Financings In Brief: ImmunoTherapeutics
Executive Summary
ImmunoTherapeutics: Fargo, N.D. company announces agreement in principle with two biotech investment funds to invest $1 mil. in exchange for 5 mil. newly issued shares of common stock. Agreement in principle is with Aries Trust and Aries Domestic Fund. Under a separate agreement with a private investor, Aries Funds agree to buy an additional 4 mil. ImmunoTherapeutics shares held by the investor. Following expected closing on June 21, Aries Funds will own 9 mil. shares of ImmunoTherapeutics stock total. Development-stage firm is investigating immunopharmaceuticals and adjuvants for cancer and other disease therapies...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth